Synergistic Cancer Treatment Systems
Legal Citation
Summary of the Inventive Concept
The present invention relates to novel systems for treating cancer by combining pharmaceutical compositions containing tucaresol or its analogs with distinct technologies, such as AI, IoT, blockchain, and new materials, to create a more powerful and effective treatment approach.
Background and Problem Solved
The original patent disclosed pharmaceutical compositions containing tucaresol or its analogs for treating cancer. However, the patent did not provide a comprehensive solution for tracking patient responses, analyzing genomic data, or optimizing treatment regimens. The present invention addresses these limitations by integrating the patented compositions with other distinct technologies to create a more holistic treatment approach.
Detailed Description of the Inventive Concept
The new inventive concept comprises systems and methods for treating cancer that integrate pharmaceutical compositions containing tucaresol or its analogs with AI, IoT, blockchain, and new materials. For example, a system may include a blockchain-based data management platform for tracking patient responses to the composition, an AI-powered analysis of a patient's genomic data to personalize treatment, or an IoT device for monitoring patient vital signs. The inventive concept enables a more targeted, efficient, and effective treatment approach by leveraging the strengths of each technology.
Novelty and Inventive Step
The new claims introduce a novel combination of the patented pharmaceutical compositions with distinct technologies, such as AI, IoT, blockchain, and new materials. This integration provides a non-obvious solution to the limitations of the original patent, as it enables a more comprehensive and effective treatment approach.
Alternative Embodiments and Variations
Alternative embodiments of the inventive concept may include integrating the pharmaceutical compositions with other technologies, such as robotics, nanotechnology, or 3D printing. Variations of the inventive concept may also include using different types of cancer or different patient populations.
Potential Commercial Applications and Market
The inventive concept has significant commercial potential in the cancer treatment market, particularly in the areas of personalized medicine, precision oncology, and digital health. The target industries include pharmaceutical companies, healthcare providers, and medical technology companies.
CPC Classifications
| Section | Class | Group |
|---|---|---|
| A | A61 | A61K31/192 |
| A | A61 | A61K31/496 |
| A | A61 | A61K39/3955 |
| A | A61 | A61P35/00 |
| C | C07 | C07K16/2818 |
| C | C07 | C07K16/2827 |
| A | A61 | A61K2039/505 |
Section 103 Obviousness Analysis (PHOSITA)
Field of Art
Pharmaceutical oncology and immunotherapy, with expertise in cancer treatment compositions, immune checkpoint inhibitors, and computational healthcare technologies
Person of Ordinary Skill (PHOSITA) Profile
A professional with advanced degrees in pharmaceutical sciences, oncology, or biomedical engineering, possessing knowledge of cancer immunotherapies, computational methods, and interdisciplinary medical technologies
Obviousness Rationale
A PHOSITA would recognize that integrating digital technologies with pharmaceutical compositions represents a natural progression in personalized medicine. The source patent's focus on tucaresol and immune checkpoint inhibitors provides a clear foundation for exploring technological augmentations to treatment protocols. The disclosed variations demonstrate predictable combinations of known technologies that enhance treatment monitoring, personalization, and efficacy tracking.
Obvious Combinations & Variations
Original Patent Information
| Patent Number | US 11,857,522 |
|---|---|
| Title | Compositions containing tucaresol or its analogs |
| Assignee(s) | BeyondSpring Pharmaceuticals, Inc. |